ASX Share rice
Sun 16 May 2021 - 12:35:am (Sydney)

PYC Share Price

PYC THERAPEUTICS LIMITEDPYCPharmaceuticals, Biotechnology & Life Sciences

PYC Company Information

Name:

PYC Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

Harry Perkins Institute of Medical Resea Nedlands WA Australia 6009

Phone:

61 8 6151 0994

CEO & Director:

Dr. Rohan Hockings MBBS, MBBS (Hons.), J.D., G.D.L.P

Company Sec. & CFO:

Mr. Kevin Hart B.Com., F.C.A., B.Com, FCA

Chief Scientific Officer:

Prof. Sue Fletcher

CEO of US operations & Director:

Mr. Sahm Nasseri M.B.A., MBA

Chief Bus. Officer:

Mr. Kaggen Ausma L.L.B.

Chief Medical Officer of US Operations:

Dr. May Orfali

Chief Devel. Officer:

Dr. Glenn Noronha

Company Overview:

PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

PYC Share Price Information

Shares Issued:

3.17B

Market Capitalisation:

$475.64M

Revenue (TTM):

$120.85K

Earnings per Share:

$-0.002

Operating Margin (TTM):

$-109.41

Return On Assets (TTM):

$-0.17

Return On Equity (TTM):

$-0.26

Quarterly Revenue Growth (YOY):

-0.091

Gross Profit(TTM):

$-2,340,474

Diluted Earnings Per Share (TTM):

$-0.004

PYC CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-13,666,199

Change To Liabilities:

$21K

Total Cashflow From Investing Activities:

$-13,772,296

Net Borrowings:

$-145,196

Net Income:

$-6,822,215

Total Cash From Operating Activities:

$-5,748,405

Depreciation:

$547.11K

Other Cashflow From Investing Activities:

$-13,666,200

Change To Account Receivables:

$-96,054

Sale Purchase Of Stock:

$26.88M

Capital Expenditures:

$106.10K

PYC Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-9,475,250

Net Income:

$-6,822,220

Gross Profit:

$-1,904,360

Operating Income:

$-9,682,280

Other Operating Expenses:

$410.64K

Income Tax Expense:

$-2,395,706

Total Revenue:

$62.50K

Cost Of Revenue:

$1.97M

PYC Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$4.85M

Total Liabilities:

$3.59M

Total Stockholder Equity:

$27.95M

Other Current Liabilities:

$72.06K

Total Assets:

$31.55M

Common Stock:

$87.21M

Retained Earnings:

$-63,749,707

Cash:

$7.24M

Total Current Liabilities:

$705.61K

Property - Plant & Equipment:

$1.14M

Net Tangible Assets:

$23.10M

Long-Term Investments:

$300K

Total Current Assets:

$25.56M

Net Receivables:

$82.67K

Short-Term Investments:

$6.29M

Accounts Payable:

$97.29K

Non Currrent Assets (Other):

$299.90K

Short-Term Investments:

$6.29

Non Current Liabilities Total:

$645.18K

PYC Share Price History

PYC News

04 May, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the Company has been invited to present two poster presentations at the Association for Research in Vision and Opthalmology (ARVO) 2021 Annual Meeting, taking place virtually May 1–7, 2021.
30 Apr, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced a first quarter update highlighting the progress of its development pipeline, growth of its U.S. operations and upcoming milestones.
12 Apr, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the results of preclinical research demonstrating the ability of its breakthrough PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology to deliver superior levels of RNA therapeutic to cells throughout the brain.
11 Apr, 2021
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, PYC Therapeutics...
06 Apr, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced it will host an investor call on April 15, 2021 at 10 am AEST | 8 am AWST (April 14, 8pm U.S. ET) to discuss corporate and pipeline updates.
29 Mar, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Jason Haddock to its Board of Directors. Mr. Haddock brings more than two decades of financial, commercial and operational leadership experience in the biopharmaceutical industry, and currently serves as a Board Director of Codiak BioSciences, a biotech company developing precision exosome therapeutics.
22 Mar, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced it was invited to participate as one of a select group of companies at the SVB Leerink Biopharma Private Company Connect, taking place virtually on March 25-26, 2021.
17 Mar, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Michael Rosenblatt, MD, to its Board of Directors. Dr. Rosenblatt is a Senior Partner at Flagship Pioneering, a leading-edge innovation organization that conceives, creates and develops first-in-category life science companies, and the former Chief Medical Officer of Merck, one of the world's leading global biopharmaceutical companies.
02 Mar, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced that the Company's lead investigational drug, VP-001, for the treatment of RP11 has restored function of the Retinal Pigment Epithelium, the target cells for the therapy, in patient-derived models of the disease.
23 Feb, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Glenn Noronha, PhD, as Chief Development Officer. Dr. Noronha will oversee the Company's translational clinical development, regulatory, manufacturing and preclinical development activities as it advances its pipeline of multiple drug candidates which is initially focused on inherited ocular diseases.
22 Feb, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development.
11 Feb, 2021
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced that Sahm Nasseri, incoming Chief Executive Officer of U.S. Operations, has been invited to participate in a virtual panel discussion and Q&A at the 2021 BIO CEO & Investor Digital Conference. The panel, titled "Turning RNA Research into Medicines," will be aired on Wednesday, February 17, at 3:00 p.m. ET.
10 Jan, 2021
The big shareholder groups in PYC Therapeutics Limited ( ASX:PYC ) have power over the company. Large companies usually...
13 Oct, 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, PYC Therapeutics...
13 Jul, 2020
A look at the shareholders of PYC Therapeutics Limited (ASX:PYC) can tell us which group is most powerful. Insiders...